Author

Jaffer Ajani

UT M. D. Anderson Cancer Center - Cited by 1,03,487 - Oncology

Biography

Dr. Jaffer Ajani is an Associate professor in the 3GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas , USA. His study interests major on Medical Oncology. In recent years, he has studied several on  Oncology, DNA damage, Peripheral blood lymphocytes. Currently, Dr. Ajani is the author/editors/reviewer in several international journals. He published 173 articles in many journals and the articles are informative and got good citations.
Title
Cited by
Year
Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction …
K Shitara, F Lordick, YJ Bang, P Enzinger, D Ilson, MA Shah, ...The Lancet 401 (10389), 1655-1668, 2023202
29
2023
Zolbetuximab+ mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+(CLDN18. 2+)/HER2− locally advanced (LA) unresectable or metastatic gastric or …
K Shitara, F Lordick, YJ Bang, PC Enzinger, DH Ilson, MA Shah, ...Journal of Clinical Oncology 41 (4_suppl), LBA292-LBA292, 2023202
11
2023
Zolbetuximab+ CAPOX in 1L claudin-18.2+(CLDN18. 2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 …
R Xu, K Shitara, JA Ajani, YJ Bang, PC Enzinger, DH Ilson, F Lordick, ...Journal of Clinical Oncology 41 (36_suppl), 40536-40536, 2023202
7
2023
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
Y Chu, E Dai, Y Li, G Han, G Pei, DR Ingram, K Thakkar, JJ Qin, M Dang, ...Nature Medicine, 1-13, 2023202
5
2023
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
JA Ajani, TA D’Amico, DJ Bentrem, D Cooke, C Corvera, P Das, ...Journal of the National Comprehensive Cancer Network 21 (4), 393-422, 2023202
5
2023
Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment
Y Fan, Y Li, X Yao, J Jin, A Scott, B Liu, S Wang, L Huo, Y Wang, R Wang, ...Gut 72 (4), 624-637, 2023202
5
2023
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC …
YY Janjigian, K Shitara, MH Moehler, M Garrido, C Gallardo, L Shen, ...Journal of Clinical Oncology 1 (16_suppl), 025-025, 2023202
4
2023
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo …
K Kato, JA Ajani, Y Doki, J Xu, L Wyrwicz, S Motoyama, T Ogata, ...Journal of Clinical Oncology 41 (4_suppl), 290-290, 20220
3
2023
Early stage gastric adenocarcinoma: clinical and molecular landscapes
Y Hirata, A Noorani, S Song, L Wang, JA AjaniNature Reviews Clinical Oncology, -7, 2023202
1
2023
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
AH Ko, KP Kim, JT Siveke, CD Lopez, J Lacy, EM O’Reilly, T Macarulla, ...The Oncologist 28 (6), 553-e472, 2023202
1
2023
Clinical impact of positive surgical margins in gastric adenocarcinoma in the era of preoperative therapy
Y Hirata, A Agnes, JS Estrella, M Blum Murphy, P Das, BD Minsky, ...Annals of surgical oncology, -0, 2023202
1
2023
Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma
KG Mitchell, EM Bayley, N Ikoma, MB Antonoff, RJ Mehran, R Rajaram, ...The Annals of Thoracic Surgery, 2023202
1
2023
Esophageal cancer: Is the CROSS strategy ready for history books?
MDS Sewastjanow, JE Rogers, WL Hofstetter, JA AjaniThe Journal of Thoracic and Cardiovascular Surgery 65 (3), 90-905, 2023202
1
2023

Referred From: https://scholar.google.com/citations?hl=en&user=COWBrHYAAAAJ

Cited by
Citations 103487
h-index 149
i10-index 705
Recommended Journals
Open Access Journals